Posted on November 22, 2013
Research published this week in the online edition of Cell Metabolism points to an intriguing new possible avenue of exploration for type-2 diabetes control. An enzyme, MK2 was found to worsen the two core defects in diabetes—impaired insulin sensitivity and overproduction of glucose, suggesting that a drug that inhibits the enzyme might be added to current first-line control medications. Diabetes is frequently associated with a variety of chronic pain conditions, including diabetic neuropathies, GI pain, and peripheral artery disease. Read more about the findings and implications for treatment here.